Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Canaccord Genuity Reiterates Buy Rating on Delcath Systems (DCTH)
March 27, 2024 8:09 AM EDTCanaccord Genuity analyst Bill Maughan reiterated a Buy rating and $21.00 price target on Delcath Systems (NASDAQ: DCTH).
The analyst commented, "Delcath reported 4Q23 results this morning and gave an update on the early launch of Hepzato, which came available in January for the treatment of metastatic uveal melanoma... More



